Advances in the management of locally advanced rectal cancer: A shift toward a patient-centred approach to balance outcomes and quality of life

IF 10.6 1区 医学 Q1 ONCOLOGY
Cancer treatment reviews Pub Date : 2025-11-01 Epub Date: 2025-08-19 DOI:10.1016/j.ctrv.2025.103015
Marco Airoldi , Susana Roselló , Noelia Tarazona , Marisol Huerta , Leticia Pérez-Santiago , Tania Fleitas , Vicente Pla-Martí , Alberto Puccini , Desamparados Roda , Andrés Cervantes
{"title":"Advances in the management of locally advanced rectal cancer: A shift toward a patient-centred approach to balance outcomes and quality of life","authors":"Marco Airoldi ,&nbsp;Susana Roselló ,&nbsp;Noelia Tarazona ,&nbsp;Marisol Huerta ,&nbsp;Leticia Pérez-Santiago ,&nbsp;Tania Fleitas ,&nbsp;Vicente Pla-Martí ,&nbsp;Alberto Puccini ,&nbsp;Desamparados Roda ,&nbsp;Andrés Cervantes","doi":"10.1016/j.ctrv.2025.103015","DOIUrl":null,"url":null,"abstract":"<div><div>The treatment of locally advanced rectal cancer (LARC) has undergone a significant evolution in recent years, shifting toward more selective strategies that balance oncological outcomes with quality of life (QoL) preservation. Total neoadjuvant treatment (TNT) has improved local control and reduced distant metastases, but its long-term toxicities have sparked growing interest in treatment de-escalation strategies aimed at minimizing adverse effects while maintaining efficacy. This review focuses on the therapeutic advancements for LARC, analysing both established standards and emerging innovations. We discuss the increasing adoption of organ-preserving approaches, particularly the Watch-and-Wait (WW) strategy for patients achieving a clinical complete response (cCR), and potentially the selective omission of radiotherapy in well-defined cases. Additionally, we explore and examine less invasive surgical techniques that preserve function without compromising cure rates. Beyond standard treatment approaches, we highlight the role of immunotherapy, particularly its breakthrough efficacy in LARC with deficient mismatch repair/microsatellite instability (dMMR/MSI), leading to the concept of immune-ablation: achieving complete tumor regression while sparing patients from chemotherapy, radiotherapy, and surgery. Ongoing research is investigating immunotherapy’s potential role also in proficient mismatch repair/microsatellite stable (pMMR/MSS) LARC. Finally, we discuss emerging predictive biomarkers, such as circulating tumor DNA (ctDNA) and radiomics, which might refine patient selection and guide treatment individualization. The future of LARC management lies in a precision-driven approach, where survival is optimized without compromising QoL. By embracing innovation and personalizing care, we are entering a new era where cure remains paramount, but never at the expense of the patient’s well-being.</div></div>","PeriodicalId":9537,"journal":{"name":"Cancer treatment reviews","volume":"140 ","pages":"Article 103015"},"PeriodicalIF":10.6000,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer treatment reviews","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0305737225001379","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/19 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

The treatment of locally advanced rectal cancer (LARC) has undergone a significant evolution in recent years, shifting toward more selective strategies that balance oncological outcomes with quality of life (QoL) preservation. Total neoadjuvant treatment (TNT) has improved local control and reduced distant metastases, but its long-term toxicities have sparked growing interest in treatment de-escalation strategies aimed at minimizing adverse effects while maintaining efficacy. This review focuses on the therapeutic advancements for LARC, analysing both established standards and emerging innovations. We discuss the increasing adoption of organ-preserving approaches, particularly the Watch-and-Wait (WW) strategy for patients achieving a clinical complete response (cCR), and potentially the selective omission of radiotherapy in well-defined cases. Additionally, we explore and examine less invasive surgical techniques that preserve function without compromising cure rates. Beyond standard treatment approaches, we highlight the role of immunotherapy, particularly its breakthrough efficacy in LARC with deficient mismatch repair/microsatellite instability (dMMR/MSI), leading to the concept of immune-ablation: achieving complete tumor regression while sparing patients from chemotherapy, radiotherapy, and surgery. Ongoing research is investigating immunotherapy’s potential role also in proficient mismatch repair/microsatellite stable (pMMR/MSS) LARC. Finally, we discuss emerging predictive biomarkers, such as circulating tumor DNA (ctDNA) and radiomics, which might refine patient selection and guide treatment individualization. The future of LARC management lies in a precision-driven approach, where survival is optimized without compromising QoL. By embracing innovation and personalizing care, we are entering a new era where cure remains paramount, but never at the expense of the patient’s well-being.
局部晚期直肠癌管理的进展:转向以患者为中心的方法来平衡结果和生活质量
近年来,局部晚期直肠癌(LARC)的治疗经历了重大演变,转向更具选择性的策略,以平衡肿瘤结果和生活质量(QoL)的保存。总的新辅助治疗(TNT)改善了局部控制并减少了远处转移,但其长期毒性引起了人们对治疗降级策略的兴趣,旨在尽量减少不良反应,同时保持疗效。本文综述了LARC的治疗进展,分析了现有的标准和新兴的创新。我们讨论了越来越多的器官保存方法的采用,特别是对达到临床完全缓解(cCR)的患者的观察和等待(WW)策略,以及在明确定义的病例中可能选择性省略放疗。此外,我们探索和检查微创手术技术,在不影响治愈率的情况下保留功能。除了标准治疗方法,我们强调了免疫治疗的作用,特别是其在LARC缺陷错配修复/微卫星不稳定性(dMMR/MSI)中的突破性疗效,导致了免疫消融的概念:在使患者免受化疗、放疗和手术的同时实现肿瘤完全消退。正在进行的研究正在调查免疫疗法在熟练错配修复/微卫星稳定(pMMR/MSS) LARC中的潜在作用。最后,我们讨论了新兴的预测性生物标志物,如循环肿瘤DNA (ctDNA)和放射组学,它们可能会改善患者选择和指导治疗个体化。LARC管理的未来在于一种精确驱动的方法,在不影响生活质量的情况下优化生存。通过拥抱创新和个性化护理,我们正在进入一个新的时代,在这个时代,治疗仍然是最重要的,但绝不以牺牲病人的健康为代价。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cancer treatment reviews
Cancer treatment reviews 医学-肿瘤学
CiteScore
21.40
自引率
0.80%
发文量
109
审稿时长
13 days
期刊介绍: Cancer Treatment Reviews Journal Overview: International journal focused on developments in cancer treatment research Publishes state-of-the-art, authoritative reviews to keep clinicians and researchers informed Regular Sections in Each Issue: Comments on Controversy Tumor Reviews Anti-tumor Treatments New Drugs Complications of Treatment General and Supportive Care Laboratory/Clinic Interface Submission and Editorial System: Online submission and editorial system for Cancer Treatment Reviews
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书